Oroxylin A (5,7-dihydroxy-6-methoxyflavone), which has showed multiple pharmacological effects, was semi-synthesized chemically as a pharmaceutical agent. Its impurities, degradation products and their formation pathways remain unknown. In the present study, two impurities (5,6,7-trihydroxyflavone, 5-hydroxy-6,7-dimethoxytlavone) and a degradation product (5,7-dihydroxy-8-methoxyflavone) in Oroxylin A bulk drug substance were identified, and their formation pathways were proposed. A reversed phase liquid chromatographic method for the simultaneous determination of Oroxylin A and the three compounds was developed on a C18 column using methanol-acetonitrile-0.1% acetic acid (54:23:23, v/v/v) as the mobile phase. The detection was performed at 271 nm. The method was validated to be robust, precise, specific and linear between 4 and 40 μg mL−1; the limits of detection and quantification of Oroxylin A were 0.01 and 0.04 μg mL−1, respectively. The developed method was found to be suitable to check the quality of bulk samples of Oroxylin A at the time of batch release and also during its stability studies (long term and accelerated stability).
[1]. M. Sonoda T. Nishiyama Y. Matsukawa M. Moriyasu 2004 J. Ethnopharmacol. 91 65.
[2]. Y. Chen L. Yang T.J. Lee 2000 Biochem. Pharmacol. 59 1445.
[3]. W.H. Huang A.R. Lee C.H. Yang 2006 Biosci. Biotechnol. Biochem. 70 2371.
[4]. J.Y. Kim S. Lee D.H. Kim B.R. Kim R. Park B.M. Lee 2002 J. Toxicol. Environ. Health A 65 373.
[5]. S.C. Ma J. Du P.P. But X.L. Deng Y.W. Zhang V.E. Ooi H.X. Xu S.H. Lee S.F. Lee 2002 J. Ethnopharmacol. 79 205.
[6]. Y. Hu Y. Yang Q.D. You W. Liu H.Y. Gu L. Zhao K. Zhang W. Wang X.T. Wang Q.L. Guo 2006 Biochem. Biophys. Res. Commun. 351 521.
[7]. Y. Yang Y. Hu H.Y. Gu N. Lu W. Liu Q. Qi L. Zhao X.T. Wang Q.D. You Q.L. Guo 2008 J. Pharm. Pharmacol. 60 1459.
[8]. Q. Guo , Q. You, N. Lu, Z. Li, Y. Gao, and Y. Ling, P CN101244055 (2008).
[9]. L. Zhao Z. Chen J. Wang L. Yang Q. Zhao J. Wang Q. Qi R. Mu Q.D. You Q.L. Guo 2010 Cancer Chemother. Pharmacol. 65 481.
[10]. ICH International Conference on Harmonization, Impurities in New Drug Substances Q3A(R2), Geneva, 1996.
[11]. C. Li L. Zhou G. Lin Z. Zuo 2009 J. Pharm. Biomed. Anal. 50 298.
[12]. G. Ye Y.H. Tang G.Y. Wang Z.X. Li H.Y. Zhu C.H. Ma Z.L. Sun C.G. Huang 2010 Chem. Biodivers. 7 2917.
[13]. C. Li L. Zhang G. Lin Z. Zuo 2011 J. Pharm. Biomed. Anal. 54 750.
[14]. W. Liu X. Xu F. Feng C. Wu 2011 Chromatographia 74 75.
[15]. ICH International Conference on Harmonization, Stability Testing: Photostability Testing New Drug Substances and Products (Q1B), Geneva, 1996.